Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0439 • ACR Convergence 2020
Hurried Communication and Low Patient Self-Efficacy Are Associated with Persistent Non-Adherence to SLE Medications
Ann Cameron Barr¹, Megan Clowse², Amanda Eudy³, Jennifer Rogers⁴, Rebecca Sadun³, Lisa Criscione-Schreiber⁵, Jayanth Doss³, Lena Eder⁶, Mithu Maheswaranathan³, Amy Corneli⁷, Hayden Bosworth⁷ and Kai Sun³, ¹Duke University Hospital, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Durham, NC, ⁴Duke, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University Hospital, Chapel Hill, NC, ⁷Duke University, Durham
Background/Purpose: Medication non-adherence is common among SLE patients and contributes to poor outcomes. Underrepresented racial minorities have disproportionately lower rates of medication adherence and often…
Abstract Number: 0577 • ACR Convergence 2020
Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes
Sarah Min¹, Devy Setyono², Sunghye Kim³, Feben Girma¹, Melanie Martin¹ and Rachel Wolfe¹, ¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²Emkey Arthritis and Osteoporosis Clinic, Wyomissing, PA, ³W.G. Hefner VA Medical Center, Salisbury, NC
Background/Purpose: SLE is a chronic multi-system autoimmune disease, affecting mostly women of child-bearing age and more racial minorities, with a wide spectrum of outcomes: from…
Abstract Number: 0842 • ACR Convergence 2020
mTOR Signaling Pathway Blockade and Rab4 Expression Affects Metabolism of Lupus T Cells
Tamas Faludi¹, Nick Huang¹, Manuel Duarte¹, Joshua Lewis¹ and Andras Perl¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Pro-inflammatory T-cell development underlies the pathogenesis of systemic lupus erythematosus (SLE). Activation of the mechanistic target of rapamycin (mTOR) plays a central role in…
Abstract Number: 0861 • ACR Convergence 2020
Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Kevin Thomas¹, Rufei Lu¹, Susan Macwana¹, Joan Merrill¹, Cristina Arriens¹, Eliza Chakravarty¹, Teresa Aberle¹, Holden Maecker², Paul Utz³, Joel Guthridge¹ and Judith James⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, ³Stanford University School of Medicine, Stanford, CA, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…
Abstract Number: 0975 • ACR Convergence 2020
Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
Xinghao Wang¹, Luz Blanco², Carmelo Carmona-Rivera³, Shuichiro Nakabo³, Hege Pedersen⁴, Zu-Xi Yu⁵ and Mariana Kaplan³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Canton, MI, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ⁵National Heart, Lung, and Blood Institute Pathology Core, Bethesda
Background/Purpose: Gasdermin D (GSDMD) is the key executioner of the inflammatory cell death mechanism pyroptosis. Recent reports have also implicated GSDMD in other mechanisms of…
Abstract Number: 1021 • ACR Convergence 2020
Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
Romy Kallas¹, Jessica Li², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Medical Institution, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Multiple variables are known to contribute to development of organ damage in SLE patients, including prednisone use and ethnicity. The aim of this study…
Abstract Number: 1258 • ACR Convergence 2020
Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus
Romy Kallas¹, Jessica Li², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Medical Institution, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: African-Americans have a higher incidence/prevalence of SLE, more lupus nephritis, higher rates of end stage renal disease and higher mortality than Caucasians. The aim…
Abstract Number: 1275 • ACR Convergence 2020
Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020
S. Sam Lim¹, Kristina Theis², Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Charles Helmick², Caroline Gordon³ and Cristina Drenkard⁴, ¹Emory University, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³University of Birmingham, Birmingham, England, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: An infectious disease outbreak can lead to negative physical and psychological consequences in the general public, as shown by the early COVID-19 pandemic, through…
Abstract Number: 1291 • ACR Convergence 2020
Depressed Symptomatology Persists over Time in the Majority of Systemic Lupus Erythematosus Patients and Is Independent of Disease Activity
Sara Kellahan¹, Xinliang Huang¹, Daphne Lew², Hong Xian³, Seth Eisen¹ and Alfred Kim⁴, ¹Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, ²Division of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, ³Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, ⁴Washington University School of Medicine, St. Louis, MO
Background/Purpose: Depression is a prevalent (24-30%) and significant comorbidity in patients with systemic lupus erythematosus (SLE) (1). As the American College of Rheumatology (ACR) classifies…
Abstract Number: 1461 • ACR Convergence 2020
Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills
Karin Tse¹, Mary Crimmings², Mike Donnelly², Reid Dossinger², Lauren Metelski² and Latifa Boyce², ¹Lupus Foundation of America, DC, WA, ²Lupus Foundation of America, WASHINGTON, DC
Background/Purpose: The Lupus Foundation of America developed and launched an educational email series, Take Charge, to provide people with lupus educational information, tools and resources…
Abstract Number: 1565 • ACR Convergence 2020
Joint Cartilage Damage Evaluated by Ultrasound in Patients with Systemic Lupus Erythematosus
Takehisa Ogura¹, Ayako Hirata², Yuki Inoue², Takaharu Katagiri², Yuto Takakura² and Hideto Kameda³, ¹Division of Rheumatology, Department of Internal Medicine, Toho University, Meguro-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University, Tokyo, Japan, ³Toho University, Tokyo, Japan
Background/Purpose: Arthritis in systemic lupus erythematosus (SLE) is typically non-erosive, although some patients with SLE show erosive destruction or Jaccoud’s arthropathy. Previously we have confirmed…
Abstract Number: 1676 • ACR Convergence 2020
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
Teresa Giani¹, Eve Smith², Rolando Cimaz³, Michael Beresford⁴ and Christian Hedrich², ¹AOU Meyer, Florence, Italy, ²University of Liverpool, Liverpool, United Kingdom, ³ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy, ⁴Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease,…
Abstract Number: 1787 • ACR Convergence 2020
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Joyce Hui-Yuen¹, Frank Jenkins², Kaiyu Jiang³, Susan Malkiel⁴, Betty Diamond⁴ and James Jarvis⁵, ¹Northwell LIJ Health System, Manhasset, NY, ²Northwell Health, Manhasset, ³University at Buffalo, Buffalo, NY, ⁴Northwell Health, Manhasset, NY, ⁵University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes encompass genomic regions enriched for epigenetic marks…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 1823 • ACR Convergence 2020
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
Michael Trevisonno¹, Alexander Hall¹, Cristina Sorrento¹ and Ellen M Ginzler², ¹State University of New York Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn
Background/Purpose: Mycophenolate Mofetil (MMF) has been long used in the treatment of systemic lupus Erythematosus (SLE). Despite its proven effectiveness, particularly in the treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].